

# Jai Radhakrishnan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8692520/publications.pdf>

Version: 2024-02-01

197  
papers

13,757  
citations

25034

57  
h-index

23533

111  
g-index

221  
all docs

221  
docs citations

221  
times ranked

14014  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Predictors and Prognosis of Recurrent IgA Nephropathy in the Kidney Allograft. Glomerular Diseases, 2022, 2, 42-53.	1.0	9
2	Six Years of KI Reports: Milestones Behind and Ahead. Kidney International Reports, 2022, 7, 1-2.	0.8	0
3	Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis. Kidney Medicine, 2022, 4, 100457.	2.0	6
4	Impact of bone marrow minimal residual disease status on quality of organ response in systemic <scp>AL</scp> amyloidosis. American Journal of Hematology, 2022, 97, .	4.1	1
5	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. JACC: Cardiovascular Interventions, 2022, 15, 753-766.	2.9	31
6	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	4.5	4
7	A challenge to the kidney community by a man-made crisis. Kidney International, 2022, 101, 854-855.	5.2	3
8	International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. Kidney International Reports, 2022, 7, 2076-2080.	0.8	1
9	Strategies for Renal Protection in Cardiovascular Interventions. Korean Circulation Journal, 2022, 52, 485.	1.9	2
10	Diagnosis and Treatment of Patients With FSGS/SRNS: A Delphi Survey. Kidney International Reports, 2022, , .	0.8	0
11	Patient perspectives and involvement in precision medicine research. Kidney International, 2021, 99, 511-514.	5.2	5
12	Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology. Kidney International, 2021, 99, 2-4.	5.2	1
13	Rationale and design of the Kidney Precision Medicine Project. Kidney International, 2021, 99, 498-510.	5.2	94
14	Reflections and Next Stages for Kidney International Reports. Kidney International Reports, 2021, 6, 1-2.	0.8	1
15	Risk factors for chronic kidney disease following acute kidney injury in pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 1665-1673.	2.4	3
16	Looking back and moving forward. Kidney International, 2021, 99, 787-790.	5.2	1
17	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.8	39
18	Late Relapses of Membranous Nephropathy: A Case Series. Kidney360, 2021, 2, 974-982.	2.1	0

#	ARTICLE	IF	CITATIONS
19	Five Years (and Counting) of Expanding Access to Kidney Disease Research. <i>Kidney International Reports</i> , 2021, 6, 1487-1488.	0.8	0
20	The Case   Euglycemic ketoacidosis in a patient on continuous renal replacement therapy. <i>Kidney International</i> , 2021, 99, 1507-1508.	5.2	2
21	Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology. <i>ASAIO Journal</i> , 2021, 67, 1087-1096.	1.6	5
22	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	13.7	197
23	Successful Use of Arteriovenous Graft for Hemodialysis Access After Left Ventricular Assist Device Placement. <i>Kidney Medicine</i> , 2021, 3, 1091-1094.	2.0	1
24	Concurrent Anti-“Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series. <i>American Journal of Kidney Diseases</i> , 2021, 78, 219-225.e1.	1.9	16
25	Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. <i>Kidney International</i> , 2021, 100, 440-446.	5.2	17
26	Pharmacological Effects of Exâ€‰%Vivo Mesenchymal Stem Cell Immunotherapy in Patients with Acute Kidney Injury and Underlying Systemic Inflammation. <i>Stem Cells Translational Medicine</i> , 2021, 10, 1588-1601.	3.3	9
27	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	5.2	782
28	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, 753-779.	5.2	325
29	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. <i>Kidney International</i> , 2021, 100, 881-893.	5.2	7
30	A pharmacistâ€physician collaborative care model in chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2021, 23, 2026-2029.	2.0	6
31	A focus group study of self-management in patients with glomerular disease.. <i>Kidney International Reports</i> , 2021, 7, 56-67.	0.8	2
32	ANCA Vasculitis Treatment in the Dialysis Patient. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1617-1619.	4.5	0
33	Low glomerular filtration rate in apparently healthy young individuals is an important factor preventing kidney transplantation from living kidney donors â€ A single-center observational study from India. <i>Indian Journal of Transplantation</i> , 2021, 15, 325.	0.1	0
34	Kidney International Reports: Three Years of Publication. <i>Kidney International Reports</i> , 2020, 5, 117.	0.8	1
35	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	5.8	37
36	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. <i>Kidney International Reports</i> , 2020, 5, 1679-1689.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Postmortem Kidney Pathology Findings in Patients with COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 2158-2167.	6.1	241
38	Dashboards to Facilitate Nephrology Disaster Planning in the COVID-19 Era. Kidney International Reports, 2020, 5, 1298-1302.	0.8	7
39	Reversal of Donor Hepatitis C Virus-Related Mesangial Proliferative GN in a Kidney Transplant Recipient. Journal of the American Society of Nephrology: JASN, 2020, 31, 2246-2249.	6.1	2
40	A Newly Recognized Endemic Region of CKD of Undetermined Etiology (CKDu) in South India-“Tondaimandalam Nephropathy”. Kidney International Reports, 2020, 5, 2066-2073.	0.8	14
41	Optimizing Kidney Replacement Therapy During the COVID-19 Pandemic Across a Complex Healthcare System. Frontiers in Medicine, 2020, 7, 604182.	2.6	7
42	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	4.5	66
43	Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series. American Journal of Kidney Diseases, 2020, 76, 374-383.	1.9	21
44	Pilot Study of Return of Genetic Results to Patients in Adult Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 651-664.	4.5	28
45	Presentation and Outcomes of Patients with ESKD and COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 1409-1415.	6.1	270
46	The Case   A hidden deposit. Kidney International, 2020, 97, 815-816.	5.2	0
47	Kidney International and the COVID-19 infection. Kidney International, 2020, 97, 823.	5.2	1
48	Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Kidney International Reports, 2020, 5, 1149-1160.	0.8	184
49	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.8	2
50	Treatment of glomerular diseases: pioneering clinical trials. Kidney International, 2020, 97, 433-436.	5.2	0
51	Cystatin C- Versus Creatinine-Based Assessment of Renal Function and Prediction of Early Outcomes Among Patients With a Left Ventricular Assist Device. Circulation: Heart Failure, 2020, 13, e006326.	3.9	22
52	How COVID-19 Has Changed the Management of Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 876-879.	4.5	23
53	Early experience with COVID-19 in kidney transplantation. Kidney International, 2020, 97, 1074-1075.	5.2	41
54	The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1066-1072.	4.5	17

#	ARTICLE	IF	CITATIONS
55	High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PLoS ONE, 2020, 15, e0244131.	2.5	46
56	One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 115-116.	3.0	24
57	TCT-32 Clinical Outcomes of Imaging- and Physiology-Guided PCI Without Contrast Administration in Advanced Renal Failure. Journal of the American College of Cardiology, 2019, 74, B32.	2.8	2
58	Anticomplement therapies in “secondary thrombotic microangiopathies” ready for prime time?. Kidney International, 2019, 96, 833-835.	5.2	5
59	Association Between Declined Offers of Deceased Donor Kidney Allograft and Outcomes in Kidney Transplant Candidates. JAMA Network Open, 2019, 2, e1910312.	5.9	78
60	Standardized Outcomes in Nephrology “Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International, 2019, 95, 1280-1283.	5.2	20
61	Genomic Mismatch at <i>LIMS1</i> Locus and Kidney Allograft Rejection. New England Journal of Medicine, 2019, 380, 1918-1928.	27.0	63
62	In-Hospital Survival and Neurological Recovery Among Patients Requiring Renal Replacement Therapy in Post “Cardiac Arrest Period. Kidney International Reports, 2019, 4, 674-678.	0.8	8
63	Capillary leak syndrome: a cytokine and catecholamine storm?. Kidney International, 2019, 95, 1009-1011.	5.2	10
64	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
65	Intensive BP control and incident kidney disease: what can we learn from “urinary” biomarkers?. Kidney International, 2019, 95, 1007-1009.	5.2	0
66	KI Reports in 2019: Further Expanding Access to Research in Nephrology. Kidney International Reports, 2019, 4, 1-2.	0.8	1
67	Citius, altius, fortius . . . faster, higher, stronger. Kidney International, 2019, 95, 476-478.	5.2	4
68	Ultra-low-contrast angiography in patients with advanced chronic kidney disease and previous coronary artery bypass surgery. Coronary Artery Disease, 2019, 30, 346-351.	0.7	5
69	Diagnostic Utility of Exome Sequencing for Kidney Disease. New England Journal of Medicine, 2019, 380, 142-151.	27.0	456
70	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	1.9	68
71	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
72	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135

#	ARTICLE	IF	CITATIONS
73	Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience. Blood, 2019, 134, 5565-5565.	1.4	0
74	C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney International, 2018, 93, 977-985.	5.2	123
75	Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis ofÂdeÂnovo collapsing glomerulopathy in renalÂallografts. Kidney International, 2018, 94, 1189-1198.	5.2	36
76	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. Journal of the American Society of Nephrology: JASN, 2018, 29, 2745-2754.	6.1	128
77	Procurement Biopsies in the Evaluation of Deceased Donor Kidneys. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1876-1885.	4.5	57
78	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39
79	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	13.7	526
80	Persistent Hepatitis C Virusâ~Associated Cryoglobulinemic Glomerulonephritis inÂPatients Successfully Treated WithÂDirect-Acting Antiviral Therapy. Kidney International Reports, 2018, 3, 985-990.	0.8	11
81	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. Annals of Internal Medicine, 2018, 168, 100.	3.9	154
82	Kidney International Reports: Two Years of Publication. Kidney International Reports, 2018, 3, 509.	0.8	0
83	Pathogenesis of SLE Nephritis in the Era of Precision Medicine. Current Rheumatology Reviews, 2018, 14, 140-144.	0.8	4
84	KI Reports and World KidneyÂDay. Kidney International Reports, 2017, 2, 125-126.	0.8	1
85	Importance of stratifying acute kidney injury in cardiogenic shock resuscitated with mechanical circulatory support therapy. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 856-864.e4.	0.8	30
86	A 31-Year-Old Man With a Ring-Enhancing Brain Lesion. Journal of Neuro-Ophthalmology, 2017, 37, 172-175.	0.8	0
87	A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. Kidney International Reports, 2017, 2, 800-810.	0.8	89
88	A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney International, 2017, 91, 787-789.	5.2	161
89	Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney International, 2017, 92, 37-46.	5.2	220
90	Kidney International Reports : The First Year. Kidney International Reports, 2017, 2, 503.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Association between Reperfusion Renal Allograft Biopsy Findings and Transplant Outcomes. Journal of the American Society of Nephrology: JASN, 2017, 28, 3109-3117.	6.1	39
92	Cryofibrinogen-Associated Glomerulonephritis. American Journal of Kidney Diseases, 2017, 69, 302-308.	1.9	12
93	Temporal Changes in Post-Infectious Glomerulonephritis in Japan (1976-2009). PLoS ONE, 2016, 11, e0157356.	2.5	5
94	Native Valve Emphysematous Endocarditis Caused by Finegoldia magna in a Novel Pathogenic Role. Infectious Diseases in Clinical Practice, 2016, 24, 57-59.	0.3	2
95	Good news and best wishes for 2016 to the global nephrology community from Kidney International. Kidney International, 2016, 89, 2.	5.2	0
96	The Launch of Kidney International Reports. Kidney International Reports, 2016, 1, 1-2.	0.8	0
97	Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1278-1287.	6.1	210
98	Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. Blood, 2016, 128, 643-643.	1.4	12
99	Live Donor Renal Anatomic Asymmetry and Posttransplant Renal Function. Transplantation, 2015, 99, e66-e74.	1.0	14
100	The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome. Frontiers in Pediatrics, 2015, 3, 78.	1.9	21
101	Proteinuria as a surrogate marker for renal outcome: are we there yet?. Kidney International, 2015, 88, 1228-1230.	5.2	11
102	Monoclonal IgG1 $\kappa$ Anti- $\alpha$ Glomerular Basement Membrane Disease: A Case Report. American Journal of Kidney Diseases, 2015, 65, 322-326.	1.9	21
103	Drug-Induced Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1287-1290.	4.5	39
104	Drug-Induced Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1300-1310.	4.5	75
105	The Author Replies:. Kidney International, 2015, 87, 664.	5.2	0
106	Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?. Heart Failure Reviews, 2015, 20, 283-290.	3.9	13
107	Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. Blood, 2015, 126, 188-188.	1.4	18
108	Predictors of outcome for severe IgA Nephropathy in a multi-ethnic U.S. cohort. Clinical Nephrology, 2015, 84 (2015), 145-155.	0.7	13

#	ARTICLE	IF	CITATIONS
109	The Authors Reply:. Kidney International, 2014, 85, 214.	5.2	2
110	Rituximab treatment for fibrillary glomerulonephritis. Nephrology Dialysis Transplantation, 2014, 29, 1925-1931.	0.7	47
111	The Evolution of Treating Glomerular Diseases: Letting Science Lead the Way. Advances in Chronic Kidney Disease, 2014, 21, 119-120.	1.4	0
112	Glomerular Diseases Associated With Cancer, Chemotherapy, and Hematopoietic Stem Cell Transplantation. Advances in Chronic Kidney Disease, 2014, 21, 48-55.	1.4	36
113	IgA Nephropathy with Minimal Change Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1033-1039.	4.5	49
114	The Treatment of Idiopathic Focal Segmental Glomerulosclerosis in Adults. Advances in Chronic Kidney Disease, 2014, 21, 434-441.	1.4	18
115	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney International, 2014, 86, 246-250.	5.2	84
116	Is Newer Safer? Adverse Events Associated with First-Line Therapies for ANCA-Associated Vasculitis and Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1657-1667.	4.5	26
117	Hemoglobinuric acute kidney injury from aortic root graft malfunction. Clinical Nephrology, 2014, 82, 221-4.	0.7	3
118	Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney International, 2013, 84, 34-44.	5.2	106
119	Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 136-137.	4.5	1
120	Lupus Nephritis: Treatment of Resistant Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 154-161.	4.5	24
121	Trimethoprim-Associated Hyponatremia. American Journal of Kidney Diseases, 2013, 62, 1188-1192.	1.9	26
122	The Treatment of Minimal Change Disease in Adults. Journal of the American Society of Nephrology: JASN, 2013, 24, 702-711.	6.1	116
123	Bacterial infectionâ€related glomerulonephritis in adults. Kidney International, 2013, 83, 792-803.	5.2	196
124	Impact of the National Institutes of Health Focal Segmental Glomerulosclerosis (NIH FSGS) clinical trial on the treatment of steroid-resistant FSGS. Nephrology Dialysis Transplantation, 2013, 28, 527-534.	0.7	8
125	The Modern Spectrum of Renal Biopsy Findings in Patients with Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1718-1724.	4.5	227
126	The Authors Reply:. Kidney International, 2013, 83, 969.	5.2	0



#	ARTICLE	IF	CITATIONS
127	The relevance of congestion in the cardio-renal syndrome. <i>Kidney International</i> , 2013, 83, 384-391.	5.2	80
128	Treatment of Idiopathic FSGS with Adrenocorticotrophic Hormone Gel. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2072-2081.	4.5	86
129	The changing pattern of glomerular disease in HIV and Hepatitis C co-infected patients in the era of HAART. <i>Clinical Nephrology</i> , 2013, 79, 285-291.	0.7	15
130	Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?. <i>Kidney International</i> , 2012, 82, 1256-1260.	5.2	13
131	Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction. <i>Clinical Nephrology</i> , 2012, 77, 366-375.	0.7	18
132	Venous Thromboembolism and Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 3-4.	4.5	7
133	Idiopathic Membranous Nephropathy: Clinical and Histologic Prognostic Features and Treatment Patterns over Time at a Tertiary Referral Center. <i>American Journal of Nephrology</i> , 2012, 36, 78-89.	3.1	31
134	Donor-Specific Antibodies Adversely Affect Kidney Allograft Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 2061-2071.	6.1	234
135	The KDIGO practice guideline on glomerulonephritis: reading between the (guide)linesâ€”application to the individual patient. <i>Kidney International</i> , 2012, 82, 840-856.	5.2	332
136	Renal-limited 'lupus-like' nephritis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2337-2342.	0.7	50
137	Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. <i>Nature</i> , 2012, 482, 98-102.	27.8	560
138	Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 748-756.	4.5	295
139	Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 338-345.	2.3	35
140	Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Mortality and Identifies Acute Kidney Injury in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2362-2370.	2.3	145
141	The pathophysiology of edema formation in the nephrotic syndrome. <i>Kidney International</i> , 2012, 82, 635-642.	5.2	102
142	Radiographic Periodontal Bone Loss in Chronic Kidney Disease. <i>Journal of Periodontology</i> , 2012, 83, 602-611.	3.4	19
143	Treatment of Resistant Glomerular Diseases with Adrenocorticotrophic Hormone Gel: A Prospective Trial. <i>American Journal of Nephrology</i> , 2012, 36, 58-67.	3.1	83
144	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH) gel. <i>Drug Design, Development and Therapy</i> , 2011, 5, 147.	4.3	83

#	ARTICLE	IF	CITATIONS
145	ANCA-associated glomerulonephritis in the very elderly. <i>Kidney International</i> , 2011, 79, 757-764.	5.2	77
146	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH). <i>Discovery Medicine</i> , 2011, 12, 91-6.	0.5	22
147	Treating lupus in the kidney: where are we now, and where are we going?. <i>Discovery Medicine</i> , 2011, 12, 341-9.	0.5	4
148	The Role of Kidney Biopsy in Heart Transplant Candidates With Kidney Disease. <i>Transplantation</i> , 2010, 89, 887-893.	1.0	40
149	Renal Transplantation in Familial Dysautonomia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1676-1680.	4.5	15
150	Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. <i>Kidney International</i> , 2010, 78, 1171-1177.	5.2	257
151	Case 5-2010. <i>New England Journal of Medicine</i> , 2010, 362, 636-646.	27.0	11
152	Under-documentation of chronic kidney disease in the electronic health record in outpatients. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2010, 17, 588-594.	4.4	39
153	Glomerular disease: why is there a dearth of high quality clinical trials?. <i>Kidney International</i> , 2010, 78, 337-342.	5.2	36
154	Do meta-analyses in nephrology change the way we treat patients?. <i>Kidney International</i> , 2010, 78, 1080-1087.	5.2	8
155	Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. <i>Kidney International</i> , 2010, 77, 152-160.	5.2	167
156	Pathologic Classification of Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 556-563.	6.1	1,191
157	Gastrointestinal disorders and renal failure: exploring the connection. <i>Nature Reviews Nephrology</i> , 2010, 6, 480-492.	9.6	68
158	Polycystic liver disease treated with therapeutic excision. <i>Kidney International</i> , 2009, 76, 803.	5.2	0
159	A case of nephrocalcinosis. <i>Kidney International</i> , 2009, 75, 856-859.	5.2	1
160	Back-bench split of a deceased-donor horseshoe kidney for two transplant recipients. <i>Kidney International</i> , 2009, 76, 1012.	5.2	0
161	Renal Biopsy in the Very Elderly. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1073-1082.	4.5	124
162	Worth a Second Look. <i>American Journal of Medicine</i> , 2009, 122, 24-26.	1.5	14

#	ARTICLE	IF	CITATIONS
163	A 56-year-old woman with sarcoidosis and acute renal failure. <i>Kidney International</i> , 2008, 74, 817-821.	5.2	13
164	Transjugular Intrahepatic Portosystemic Shunts in Hemodialysis-dependent Patients and Patients with Advanced Renal Insufficiency: Safety, Caution, and Encephalopathy. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 516-520.	0.5	17
165	The Case of Renal failure after percutaneous closure of a perivalvular leak. <i>Kidney International</i> , 2008, 74, 539-540.	5.2	3
166	Oxalate Nephropathy Complicating Roux-en-Y Gastric Bypass. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1676-1683.	4.5	180
167	Towards the Incidence of Acute Phosphate Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 3020-3022.	6.1	26
168	Cardiac Transplantation Using Extended-Donor Criteria Organs for Systemic Amyloidosis Complicated by Heart Failure. <i>Transplantation</i> , 2007, 83, 539-545.	1.0	73
169	Rituximab Treatment of Dysproteinemias Affecting the Kidney: A Review of Three Cases. <i>American Journal of Kidney Diseases</i> , 2007, 50, 641-644.	1.9	15
170	The burden of prescription coverage of kidney failure patients in the United States: is Medicare Part D the answer?. <i>Kidney International</i> , 2006, 69, 1099-1100.	5.2	2
171	Mycophenolate Mofetil for the Treatment of Interstitial Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 718-722.	4.5	95
172	Race/Ethnicity, Poverty Status, and Renal Transplant Outcomes. <i>Transplantation</i> , 2005, 80, 917-924.	1.0	71
173	Use of Mycophenolate Mofetil in Autoimmune and Renal Diseases. <i>Transplantation</i> , 2005, 80, S265-S271.	1.0	62
174	Acute Phosphate Nephropathy following Oral Sodium Phosphate Bowel Purgative. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3389-3396.	6.1	358
175	Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2139-2145.	0.7	195
176	De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 203-209.	0.7	50
177	An overlapping etiology of rapidly progressive glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2004, 43, 388-393.	1.9	13
178	Awareness of kidney disease in the US population: Findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. <i>American Journal of Kidney Diseases</i> , 2004, 44, 185-197.	1.9	99
179	Toxic acute tubular necrosis following treatment with zoledronate (Zometa). <i>Kidney International</i> , 2003, 64, 281-289.	5.2	333
180	Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. <i>Seminars in Nephrology</i> , 2003, 23, 406-411.	1.6	42

#	ARTICLE	IF	CITATIONS
181	Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study. Diabetes Care, 2003, 26, 1402-1407.	8.6	99
182	Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrology Dialysis Transplantation, 2003, 18, 2039-2046.	0.7	172
183	Nephrological and obstetric complications of the antiphospholipid syndrome. Expert Opinion on Investigational Drugs, 2002, 11, 819-829.	4.1	6
184	Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation, 2002, 73, 783-788.	1.0	70
185	Thrombotic microangiopathies. Critical Care Clinics, 2002, 18, 309-320.	2.6	30
186	Fludarabine treatment of cryoglobulinemic glomerulonephritis. American Journal of Kidney Diseases, 2002, 40, 644-648.	1.9	9
187	A rare infectious cause of renal allograft dysfunction. American Journal of Kidney Diseases, 2002, 40, 1103-1107.	1.9	14
188	Advances in the Treatment of Lupus Nephritis. Annual Review of Medicine, 2001, 52, 63-78.	12.2	57
189	Antiphospholipid antibody syndrome and renal disease. Current Opinion in Nephrology and Hypertension, 2001, 10, 175-181.	2.0	39
190	Racial and socioeconomic factors in glomerular disease. Seminars in Nephrology, 2001, 21, 403-410.	1.6	19
191	Use of mycophenolate mofetil in resistant membranous nephropathy. American Journal of Kidney Diseases, 2000, 36, 250-256.	1.9	105
192	Cyclosporin treatment of glomerular diseases. Expert Opinion on Investigational Drugs, 2000, 9, 1053-1063.	4.1	12
193	Lithium Nephrotoxicity. Journal of the American Society of Nephrology: JASN, 2000, 11, 1439-1448.	6.1	306
194	CYCLOSPORINE TREATMENT OF GLOMERULAR DISEASES. Annual Review of Medicine, 1999, 50, 1-15.	12.2	31
195	Renal Transplantation in Anticardiolipin Antibody-Positive Lupus Erythematosus Patients. American Journal of Kidney Diseases, 1994, 23, 286-289.	1.9	56
196	The Epidemiology of Peritonitis in Acute Peritoneal Dialysis: A Comparison Between Open- and Closed-Drainage Systems. American Journal of Kidney Diseases, 1993, 21, 300-309.	1.9	29
197	Evaluation of a computer program for teaching laboratory diagnosis of acid-base disorders. Journal of Biomedical Informatics, 1992, 25, 562-568.	0.7	6